PAX5 and lymphoma: A common set of enhancers has been found to control the expression of both ZCCHC7 and PAX5 (refs. 44,45), and we suspected that ‘enhancer retargeting (ER),’ whereby functional loss of a promoter results in subsequent preferential targeting of a different promoter35,45, could occur following aSHM at promoter regions during lymphoma progression.